http://orcid.org/0000-0002-5567-7938
References
- Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington’s disease. Cochrane Database Syst Rev 2009;3:CD006455
- Rodrigues FB, Abreu D, Damasio J, et al. Survival, mortality, causes and places of death in a European Huntington’s disease prospective cohort. Mov Disord Clin Prac 2017;4:737-42
- Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers 2015;1:15005
- Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev 2009;3:CD006456
- Travessa AM, Rodrigues FB, Mestre TA, et al. Fifteen years of clinical trials in Huntington’s disease: a very low clinical drug development success rate. J Huntingtons Dis 2017;6:157-63
- Snowden JS, Craufurd D, Griffiths HL, et al. Awareness of involuntary movements in Huntington disease. Arch Neurol 1998;55:801-5
- Ross CA, Pantelyat A, Kogan J, et al. Determinants of functional disability in huntington’s disease: role of cognitive and motor dysfunction. Mov Disord 2014;29:1351-8
- Shoulson I. Huntington disease – functional capacities in patients treated with neuroleptic and anti-depressant drugs. Neurology 1981;31:1333-5
- McCusker E, Loy CT. The many facets of unawareness in Huntington disease. Tremor Other Hyperkinet Mov (NY) 2014;4:257
- Sung VW, Iyer RG, Gandhi SK, et al. Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States. Curr Med Res Opin 2018:1-6. Available from https://www.ncbi.nlm.nih.gov/pubmed/21975581
- Burgunder JM, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s disease. PLoS Curr 2011;3:RRN1260
- Orth M, Handley OJ, Schwenke C, et al. Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY. PLoS Curr 2010;2:Rrn1184
- Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-9
- Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-72
- Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 2016;316:40-50
- Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in Huntington disease: a pilot open label study. Tremor Other Hyperkinet Mov 2012;2:1-8
- Ferrara JM, Mostile G, Hunter C, et al. Effect of tetrabenazine on motor function in patients with Huntington disease. Neurol Ther 2012;1:5
- Rodrigues FB, Duarte GS, Costa J, et al. Tetrabenazine versus deutetrabenazine for Huntington’s disease: twins or distant cousins? Eur J Neurol 2017;4:582-5
- Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord 2017;4:3
- Rodrigues FB, Duarte GS, Costa J, et al. Meta-research metrics matter: letter regarding article “indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease”. J Clin Mov Disord 2017;4:19
- Rodrigues FB, Wild EJ. Huntington’s disease clinical trials corner: February 2018. J Huntington’s Dis 2018;7:87-97
- Rodrigues FB, Wild EJ. Clinical trials corner: September 2017. J Huntington’s Dis 2017;6:255-63